# OnCo record pieris-pharmaceuticals (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/pieris-pharmaceuticals/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "pieris-pharmaceuticals" ;
  schema:name "Pieris Pharmaceuticals"@en ;
  schema:alternateName "Pieris AG"@en, "NASDAQ:PIRS"@en ;
  schema:description "Pieris Pharmaceuticals engineered small lipocalin proteins called Anticalins into cancer immunotherapies, including the HER2-targeted 4-1BB agonist cinrebafusp alfa, before merging into Palvella Therapeutics in 2024."@en ;
  schema:url <https://onco.cc/companies/pieris-pharmaceuticals/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  onco:tag "drug-maker" ;
  schema:addressCountry "US" ;
  onco:drugs <https://onco.cc/drugs/cinrebafusp-alfa/> .